1. Evaluation of XIENCE V Everolimus-Eluting and Taxus Express2 Paclitaxel-Eluting Coronary Stents in Patients With Jailed Side Branches From the SPIRIT IV Trial at 2 Years 
John K. Forrest, MD, Alexandra J. Lansky, MD, Stephanie M. Meller, BA, Liming Hou, PhD, Poornima Sood, MD, MBA, Robert J. Applegate, MD, John C. Wang, MD, Kimberly A. Skelding, MD, Aakar Shah, MS, Dean J. Kereiakes, MD, Krishnankutty Sudhir, MD, PhD, Ecaterina Cristea, MD, Manejeh Yaqub, MD, Gregg W. Stone, MD 
American Journal of Cardiology 
Volume 111, Issue 11, Pages (June 2013)
DOI: /j.amjcard
Copyright © 2013 Elsevier Inc. Terms and Conditions

2. Figure 1
Patient distribution by treatment type (XIENCE V vs Taxus Express2) and side branch information (target lesions with vs without side branches) in the SPIRIT IV trial.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2013 Elsevier Inc. Terms and Conditions

3. Figure 2
Time-to-event curves for XIENCE V and Taxus Express2 patients with jailed side branches through 2 years. (A) target lesion failure (TLF), (B) ischemia-driven target lesion revascularization (ID-TLR), (C) target vessel myocardial infarction (TV-MI), and (D) Academic Research Consortium (ARC)–defined stent thrombosis (ST) (definite [def] or probable [prob]). HR = hazard ratio.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2013 Elsevier Inc. Terms and Conditions